牛牛AI助理已提取核心訊息
Pfizer Inc., the pharmaceutical giant, filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on February 23, 2024. This filing is in connection with the company's 2019 Stock Plan following the completion of its acquisition of Seagen Inc. on December 14, 2023. The registration statement pertains to the offering and sale of an additional 67,734,387 shares of Pfizer's common stock. These shares were added to the share reserves under the 2019 Stock Plan as a result of the acquisition. The documents required for the registration statement will be delivered to the participants of the plan and are available upon request. Pfizer's recent Annual Report and other relevant documents have been incorporated by reference into this registration statement, which will be updated with any subsequent filings with the SEC.
Pfizer Inc., the pharmaceutical giant, filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on February 23, 2024. This filing is in connection with the company's 2019 Stock Plan following the completion of its acquisition of Seagen Inc. on December 14, 2023. The registration statement pertains to the offering and sale of an additional 67,734,387 shares of Pfizer's common stock. These shares were added to the share reserves under the 2019 Stock Plan as a result of the acquisition. The documents required for the registration statement will be delivered to the participants of the plan and are available upon request. Pfizer's recent Annual Report and other relevant documents have been incorporated by reference into this registration statement, which will be updated with any subsequent filings with the SEC.
製藥巨頭輝瑞公司於2024年2月23日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件與該公司在2023年12月14日完成對西根公司的收購之後的2019年股票計劃有關。註冊聲明涉及輝瑞再發行和出售67,734,387股普通股。由於此次收購，這些股票被添加到2019年股票計劃下的股票儲備中。註冊聲明所需的文件將交付給計劃的參與者，並可應要求提供。輝瑞最近的年度報告和其他相關文件已以引用方式納入本註冊聲明，該聲明將在隨後向美國證券交易委員會提交的任何文件中進行更新。
製藥巨頭輝瑞公司於2024年2月23日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件與該公司在2023年12月14日完成對西根公司的收購之後的2019年股票計劃有關。註冊聲明涉及輝瑞再發行和出售67,734,387股普通股。由於此次收購，這些股票被添加到2019年股票計劃下的股票儲備中。註冊聲明所需的文件將交付給計劃的參與者，並可應要求提供。輝瑞最近的年度報告和其他相關文件已以引用方式納入本註冊聲明，該聲明將在隨後向美國證券交易委員會提交的任何文件中進行更新。
有用
沒用